Skip to content

Study on the safety and efficacy of the ketogenic diets for stage IV advanced and recurrent cancer patients.

Study on the safety and efficacy of the ketogenic diets for stage IV advanced and recurrent cancer patients. - KDAC study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000039925
Enrollment
20
Registered
2020-03-31
Start date
2018-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All types of cancer for which PET-CT examination is indicated

Interventions

Intervention period: 1 year The criteria for a ketogenic diet are as follows: Daily carbohydrate intake: 5% or less of energy intake Daily EPA intake: 2g or more Daily protein intake: Weight x 1.6

Sponsors

Tama-Nanbu Regional Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation Department of Surgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Stage IV advanced/recurrent cancer patients who meet the following conditions (1 to 4 are essential conditions) However, combined use of anticancer drugs and radiation therapy is essential. 1. Cancers for which PET-CT is indicated 2. Eastern Cooperative Oncology Group standard performance status (PS) 0-2 3. Various organ functions are normal. 4. No weight loss in the last 3 months (less than 5%) 5. BMI is over 18kg/m2

Exclusion criteria

Exclusion criteria: Cachexia patients

Design outcomes

Primary

MeasureTime frame
Evaluated every 3 months after starting ketogenic diets RECIST assessment by CT or MRI.

Secondary

MeasureTime frame
Monthly evaluation after starting ketone meal Changes in blood sugar level, blood ketone body level, body weight, plasma albumin level, renal function (BUN, Cr), liver function (GOT, GPT), tumor marker.

Countries

Japan

Contacts

Public ContactKenji Furukawa

Tama-Nanbu Regional Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation Department of Surgery

kenji_furukawa@tokyo-hmt.jp042-338-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026